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Background: Appreciating variation in the length of pre- or post-presentation diagnostic intervals can help prioritise early
diagnosis interventions with either a community or a primary care focus.
Methods: We analysed data from the first English National Audit of Cancer Diagnosis in Primary Care on 10 953 patients with
any of 28 cancers. We calculated summary statistics for the length of the patient and the primary care interval and their ratio,
by cancer site.
Results: Interval lengths varied greatly by cancer. Laryngeal and oropharyngeal cancers had the longest median patient intervals,
whereas renal and bladder cancer had the shortest (34.5 and 30 compared with 3 and 2 days, respectively). Multiple myeloma and
gallbladder cancer had the longest median primary care intervals, and melanoma and breast cancer had the shortest (20.5 and 20
compared with 0 and 0 days, respectively). Mean patient intervals were longer than primary care intervals for most (18 of 28)
cancers, and notably so (two- to five-fold greater) for 10 cancers (breast, melanoma, testicular, vulval, cervical, endometrial,
oropharyngeal, laryngeal, ovarian and thyroid).
Conclusions: The findings support the continuing development and evaluation of public health interventions aimed at shortening
patient intervals, particularly for cancers with long patient interval and/or high patient interval over primary care interval ratio.
Most patients with cancer present with symptoms, and of those
most first present to a general practitioner (Elliss-Brookes et al,
2012; Jensen et al, 2014). For these patients, timeliness of diagnosis
is a function of both the length of time from symptom onset to first
consultation (the patient interval), and the time from first
consultation to specialist referral (the primary care interval;
Weller et al, 2012). Interventions aiming at shortening either
interval have been developed, with either a predominantly
community focus (e.g., public health interventions to help
individuals recognise, and act on, ‘alarm symptoms’) or a health-
care system focus (e.g., decision-support interventions or specialist
referral guidelines; NICE, 2005; Austoker et al, 2009; Hamilton
et al, 2013).
The relative contribution of each of the two intervals (i.e., the
patient or the primary care interval) to the length of the overall
pre-referral interval from symptom onset to referral is nonetheless
inadequately described for most cancers. The majority of the
evidence relates to methodologically heterogeneous studies exam-
ining either the patient or the primary care interval on their own,
often focussing on a single or a few cancer sites. However, some
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recent studies have encompassed multiple cancer sites, identifying
large differences between cancers in the length of various
diagnostic intervals (Baughan et al, 2009; Tokuda et al, 2009;
Hansen et al, 2011; Lyratzopoulos et al, 2013a; Keeble et al, 2014;
Neal et al, 2014). In addition, current evidence suggests that
primary care intervals tend to be very short for cancers in which
most patients present with palpable or visible symptoms and signs,
such as for breast cancer, melanoma and endometrial cancer
(Baughan et al, 2009; Lyratzopoulos et al, 2013a), which also tend
to be associated with socioeconomic inequalities in stage at
diagnosis (Lyratzopoulos et al, 2013b; Robbins et al, 2014).
These observations indicate that patient intervals may dominate
the length of overall pre-referral intervals for at least some cancers.
In contrast, the relative contribution of the primary care interval
may be greater for other cancers, particularly those in which
substantial proportions of patients present with symptoms of low
specificity and which are considered ‘harder to suspect’ after
presentation (Lyratzopoulos et al, 2012). In order to better target
interventions aiming to shorten the pre-referral interval, the
relative contribution of pre- and post-presentation intervals for
different cancers needs to be better described.
We therefore set out to comprehensively examine differences in
the length of patient and primary care intervals for a range of
common and rarer cancers. In doing so, we systematically address
variation by cancer in the length of the two intervals to help
inform decision-making about the development, implementation
and evaluation of either community- or primary care-based
interventions.
PATIENTS AND METHODS
We analysed data from the (English) National Audit of Cancer
Diagnosis in Primary Care 2009–2010. Details of the methods used
in the audit have been published previously (Rubin et al, 2011).
Briefly, using continuous sampling during the audit period, data on
aspects of the diagnostic process of cancer patients were collected
by general practitioners or other primary care professionals in an
estimated total of 1170 general practices (B14% of all practices in
England) using information included in practice patient records.
Data collection excluded screening-detected cancers and non-
melanoma skin cancer. Although practices participated voluntarily,
comparisons with cancer registration statistics indicate that the
data set is representative of the age, sex and cancer site case-mix of
incident English cancer patients (Rubin et al, 2011). Further, care
quality measures (Quality and Outcomes Framework and General
Practice Patient Survey practice scores) and other practice
characteristics were similar in participating and non-participating
practices belonging to the same (former) cancer networks
(Lyratzopoulos et al, 2013c).
Interval measures. The patient interval was defined as the period
between symptom onset and first relevant presentation, defined as
the first notification to any health-care professional working within
the primary care team about a symptom or sign that was probably
due to the cancer, based on information available in the medical
records (Rubin et al, 2011; Weller et al, 2012). The primary care
interval was defined as the period from the first relevant
symptomatic presentation to a general practitioner and their first
specialist referral for further investigation (Rubin et al, 2011;
Weller et al, 2012). For each patient, we also calculated the overall
pre-referral interval (denoting the period from symptom onset to
referral) by summing patient and primary care intervals. Informa-
tion was also available on the referral interval (the period from the
date of first consultation to the first hospital appointment for
specialist assessment).
Analysis. The analysis sample included patients aged 15 years or
older who had first presented to a general practitioner and were
subsequently diagnosed with one of 28 cancers (i.e., bladder, brain,
breast, cervical, colorectal, endometrial, gallbladder, laryngeal,
leukaemia, liver, lung, lymphoma, melanoma, mesothelioma,
myeloma, oesophageal, oropharyngeal, ovarian, pancreatic,
prostate, renal, sarcoma, small intestine, stomach, testicular,
thyroid, unknown primary or vulval cancer). We calculated the
mean, median, 25th, 75th and 90th centiles (and respective
95% confidence intervals (CIs), estimated using a bootstrap
approach) for the patient, primary care and overall pre-referral
intervals, by cancer site. Further, we calculated the ratio of the
mean patient interval to the mean primary care interval for each
cancer, and similarly the ratio of respective median values. In
supplementary analysis, for each cancer separately, we also present
information on the referral interval (date of referral to date of first
hospital appointment) and the proportion of patients with interval
values 0–14, 0–30 and 0–90 days to enable future comparisons with
literature reporting binary proportions of patients exceeding the
respective cut-off interval values.
RESULTS
Of 14 931 patients with any of the 28 cancers being considered,
who presented to a general practitioner and were older than
15, 3978 patients (26.6%) had a missing (or invalid) patient or
primary care interval value; therefore, analysis was confined
to 10 953 patients. The proportion of cases excluded because of
missing interval data waso28% for all but five cancers (leukaemia,
prostate, liver, melanoma and multiple myeloma for which it was
45%, 44%, 40%, 39% and 34%, respectively). Sample sizes for each
cancer site reflected its population incidence, ranging from 38
patients with small intestine and 40 with gallbladder cancer to 1673
patients with colorectal and 2124 with breast cancer.
Variation in the patient interval. Laryngeal and oropharyngeal
cancers had the longest median patient intervals (34.5 (95% CI: 30–
57) and 30 (95% CI 21–34) days, respectively), whereas renal
and bladder cancer had the shortest (3 (95% CI 1–5) and 2 (95%
CI 1–3) days, respectively; Table 1). Another seven cancers
(cervical, oesophageal, melanoma, thyroid, colorectal, mesothe-
lioma and vulval cancer) had median patient intervals between 17
and 25 days. In addition to variation in medians, the distribution of
the patient interval also varied between cancers. In particular, some
cancers with relatively short median patient intervals had relatively
long 75th and 90th centile intervals – for example, testicular and
small intestine cancer, with medians of 12 and 10.5 days,
respectively, but 75th centile values of 67 and 75 days. The
opposite pattern was also observed, where the median interval is
relatively long compared with other cancers, but the 75th centile is
relatively short – e.g., oesophageal cancer.
Variation in the primary care interval. Multiple myeloma and
gallbladder cancer had the longest median primary care intervals
(20.5 (95% CI 14–31) and 20 (95% CI 9–29) days, respectively)
and melanoma and breast cancer had the shortest (0 (95% CI 0–0)
days for both; Table 1). Another eight cancers had median primary
care intervals between 10 and 15 days. Similarly with the patient
interval, there is variation in the 75th and 90th centiles that is not a
direct reflection of the variation in the medians.
Variation in the overall pre-referral interval. The overall
pre-referral interval ranged from 58 (95% CI 46–66) days for
laryngeal cancer to 10 (95% CI 9–12) days for breast cancer
(Table 1). Because some patients have greater than median values
for both the patient and the primary care intervals, the median
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pre-referral intervals for patients with a given cancer are greater
than the sum of the medians of the constituent intervals.
Relative length of patient and primary care intervals. Mean and
median patient intervals were longer than mean and median
primary care intervals for most cancers (18 out of 28 and 20 out of
28, respectively; Table 1). In particular, the mean patient interval
was approximately five-fold greater than the mean primary care
interval for breast cancer, four-fold greater for melanoma and
testicular cancer, three-fold greater for vulval and cervical cancer
and two-fold greater for endometrial, oropharyngeal, laryngeal,
ovarian and thyroid cancers (Table 2). Figures 1 and 2 pictorially
summarise the patient and the primary care interval by cancer site.
Supplementary analysis. In contrast to the size of variation by
cancer in the median length of both the patient and the primary
care intervals (i.e., 34.5 vs 2 days, and 20.5 vs 0 days, respectively),
variation by cancer with respect to the referral interval was
relatively small, with maximum and minimum median values of
14 days for bladder or thyroid cancer and 5 days for leukaemia
(data not shown). Further, the proportions of patients with interval
values of 0–14, 0–30 and 0–90 days for the patient, primary care
and overall pre-referral intervals are provided in Supplementary
Online Material 2.
DISCUSSION
The length of patient and primary care intervals varies greatly by
cancer site. Moreover, the relative contribution of either interval in
the overall duration of the pre-referral period is variable, with the
average patient interval being at least two-fold longer than the
primary care interval for 10 cancers.
Comparison with other literature. Evidence about the length of
patient and primary care intervals in patients with different cancers
is sparse, because such measures do not currently form part of
population-based cancer registration systems. Therefore, as is the
case for the present study, most evidence thus far typically comes
from primary care medical record studies (Baughan et al, 2009;
Tokuda et al, 2009; Hansen et al, 2011). However, collection
of relevant information from primary care records is a time-
consuming process, and collation of data from continuous samples
is often only possible in the context of national audit initiatives –
such as the first English National Audit of Cancer Diagnosis
in Primary Care and similar previous initiatives in Scotland and
Denmark (Baughan et al, 2009; Hansen et al, 2011; Rubin et al,
2011). The present findings add to prior evidence about diagnostic
intervals, previously reported for between 10 and 18 cancers
(Baughan et al, 2009; Hansen et al, 2011; Lyratzopoulos et al,
Table 1. Summary statistics for the patient, the primary care and the pre-referral intervals expressed in number of days
(n¼10953 patients with 28 cancers)a
Patient interval (days) Primary care interval (days) Pre-referral interval (days)
Cancer
diagnosis N Mean
25th
Centile
50th
Centile
75th
Centile
90th
Centile Mean
25th
Centile
50th
Centile
75th
Centile
90th
Centile Mean
25th
Centile
50th
Centile
75th
Centile
90th
Centile
Laryngeal 94 68 12 34.5 78 183 36 0 7 28 57 104 31 58 92 234
Oropharyngeal 146 53 8 30 61 121 22 0 5.5 27 56 75 30 48 87 136
Cervical 97 77 2 25 92 265 25 0 5 26 79 102 13 45 140 293
Oesophageal 418 40 7 21.5 46 99 26 0 5 30 71 66 20 40 80 152
Melanoma 475 69 0 21 69 234 17 0 0 7 44 86 8 31 94 317
Thyroid 80 60 2 20.5 40.5 192.5 32 0 8.5 21.5 49 91 17 35 81.5 228.5
Colorectal 1673 50 1 19 61 127 32 0 6 29 90 82 16 46 97 203
Mesothelioma 57 42 3 17 34 122 24 1 7 27 84 66 21 41 80 190
Vulval 49 59 7 17 61 122 16 0 1 7 54 76 14 31 86 284
Endometrial 319 54 1 14 59 168 21 0 1 15 51 75 6 29 83 219
Liver 53 28 0 14 39 61 32 1 11 27 73 60 14 36 61 125
Lymphoma 477 39 1 14 44 94 33 0 9 31 89 72 16 38 87 186
Ovarian 275 39 2 14 52 113 21 0 7 22 51 60 14 36 72 149
Multiple
myeloma
124 44 0 13.5 31 93 56 5 20.5 62 134 100 22 46 110.5 213
Sarcoma 72 45 0 13 56.5 119 45 0 7 40.5 115 90 15 52 111 226
Testicular 112 60 2 12 67 184 15 0 1.5 16 30 75 8 24.5 94.5 212
Lung 1128 33 0 11 32 85 33 3 14 39 78 66 17 39 79 146
Small Intestine 38 43 0 10.5 75 153 26 1 10 32 90 69 12 38.5 128 184
Pancreatic 268 26 1 10 31 74 33 0 7 31.5 97 58 9 28.5 74.5 144
Stomach 187 45 0 9 38 125 46 0 12 65 134 90 15 49 126 235
Unknown
primary
111 24 0 8 23 68 33 0 15 36 75 57 14 34 67 129
Brain 121 36 1 7 26 92 22 0 4 16 56 58 5 22 61 139
Breast 2124 32 1 7 27 77 6 0 0 1 7 38 2 10 31 91
Leukaemia 228 32 0 7 30 86 25 0 4 22.5 58 57 6.5 26 68 141
Prostate 1378 47 0 7 42 151 31 2 11 26 74 78 9 32 93 209
Gallbladder 40 34 0 4.5 15.5 74 41 4.5 20 39 76 75 9 31.5 73.5 304.5
Renal 207 26 0 3 21 62 35 1 13 39 108 61 8 30 71 181
Bladder 602 22 0 2 14 61 26 0 3 15 53 48 3 14 45 134
Cancers are ordered in descending order of median patient interval. Bootstrap 95% confidence intervals for all estimates are presented in Supplementary Online Material 2.
aNote that centiles occur that are not whole numbers (non-integers) when the centile falls between two observations. In such cases the mean of the two adjacent observations is used.
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2013a; Keeble et al, 2014), by including the largest number
of cancer sites examined to date, by additionally describing overall
pre-referral intervals, and by comparing the length of patient and
primary care intervals for different cancers.
Strengths and limitations. Strengths of the study include its large
sample and the inclusion of patients with 28 common and rarer
cancers. Data have been collected by medical or nursing staff on
continuous samples of incident cancer cases during the audit
period (Rubin et al, 2011), thus minimising potential for selection
bias. The diagnostic case-mix of included patients was similar to
incident cases, and the performance and characteristics of
participating general practices were similar to non-participating
ones, both these observations indicating a representative sample
(Rubin et al, 2011; Lyratzopoulos et al, 2013c).
There are four principal limitations. First, in contrast to
information about the primary care interval (which is obtainable
from medical records in a relatively straightforward manner),
information about the patient interval requires that patients
accurately appreciate and report the duration of their symptoms,
and doctors accurately interpret and enter that information into
their medical notes. Although information about symptom
duration before presentation is nearly always elicited during
general practice consultations, inaccuracies in the measurement of
the patient interval are likely to occur, particularly in the context of
comorbid conditions. However, we assume that, although
inaccuracies in the measurement of the patient interval may vary
by symptom, they are unlikely to be systematically biased towards
either over- or under-estimating its length (Lynch et al, 2008). It is
also unlikely that inaccuracies in patient recall will be grossly
differential between patients with different cancers, given the large
overall size of the observed variation (Keeble et al, 2014). For
example, very substantial levels of differential recall accuracy between
patients with bladder and laryngeal cancer would have been required
to generate the very large difference in median patient intervals
between these two cancers (2 vs 34.5 days, respectively).
Second, we were not able to include in the analysis one in four
patients in the population of prior interest – chiefly because of
missing data about the patient interval (data now shown). Caution
is particularly required when interpreting findings for cancers with
relatively high proportions of missing interval data – for example,
leukaemia and prostate cancer (both with 440% missing interval
data). It should be noted that unlike the start of the primary care
interval, which is based on the recorded first consultation date, the
start of the patient interval was inferred using information in the
free text of the patient records. Failure by the GP to note the
duration of symptoms would make inferring the start of the patient
interval impossible. However, patterns of patient interval variation
by cancer are robust to extreme case scenario sensitivity analysis
(Keeble et al, 2014).
Third, our findings relate to a population of English cancer
patients who first attended primary care in the audit period (2009–
2010). It is therefore possible that the population values of the
reported intervals have changed to some degree since then, given
recent interventions to increase public awareness of symptoms or
provision of decision-support tools for general practitioners
(Hamilton et al, 2013; NHS, 2014).
Fourth, although our study sample is relatively large, the exact
ordering of different cancers with respect to either interval (and
consequently also their ratios) is likely to be subject to considerable
uncertainty. Rather than concentrating on the precise ordering of
cancers we focus on the overall pattern of variation, focussing
on those cancers with the shortest or the longest intervals
(and the higher interval ratios).
Implications. The findings can help inform priorities about
interventions aimed at shortening either interval. For six of the
cancers with the longest patient interval, large proportions of
patients present with fairly typical symptoms – for example,
laryngeal (voice hoarseness), oropharyngeal (oral ulcer/lesion),
oesophageal (dysphagia), melanoma (pigmented skin lesions) and
vulval (vulval ulcer/lesion). The observation that these cancers are
associated with long patient intervals despite the presence of clear-
cut symptoms in most patients subsequently diagnosed with them
would, in principle, advocate the development and evaluation of
public health campaigns aimed at raising awareness of symptoms,
and appropriate help-seeking behaviour, for these (rarer) cancers.
In England, current public health awareness interventions
thus far have not as yet encompassed most of the above ‘principal
symptom – cancer site’ pairs, possibly because of (justifiable) initial
emphasis on most common cancers (NHS, 2014), although they
could be considered in the future.
The relative contribution of the patient interval in the overall
length of the pre-referral interval is also important. Most cancers
with two-fold or greater length of patient compared with primary
care intervals are characterised by the presence of palpable, visible
or noticeable symptoms in most patients – for example, breast
(lump), melanoma (pigmented skin lesion), testicular (lump),
vulval (vulval ulcer/lesion), endometrial (vaginal bleeding, typically
post-menopausal), oropharyngeal (oral ulcer/lesion) and laryngeal
Table 2. Ratio of mean and median patient interval over mean
and median primary care interval, by cancer site
Cancer
diagnosis
Mean patient interval/
Mean primary care interval
Median patient interval/
Median primary care interval
Breast 5.2 (4.0–6.6) * (*–*)
Melanoma 4.1 (3.0–5.6) * (*–*)
Testicular 4.1 (2.3–7.3) 8.0 (1.8–*)
Vulval 3.6 (1.8–9.0) 17.0 (3.5–*)
Cervical 3.1 (1.8–5.3) 5.0 (1.3–39.0)
Endometrial 2.6 (1.8–3.8) 14.0 (9.0–*)
Oropharyngeal 2.4 (1.5–4.0) 5.5 (1.8–30.5)
Laryngeal 1.9 (1.1–3.8) 4.9 (2.4–19.3)
Ovarian 1.9 (1.4–2.6) 2.0 (1.1–2.8)
Thyroid 1.9 (1.1–4.1) 2.4 (0.9–5.3)
Brain 1.7 (0.9–3.3) 1.8 (0.8–8.0)
Mesothelioma 1.7 (1.0–3.0) 2.4 (0.7–6.0)
Small intestine 1.7 (0.8–3.3) 1.1 (0.2–4.1)
Colorectal 1.6 (1.4–1.8) 3.2 (2.6–4.5)
Oesophageal 1.5 (1.2–1.9) 4.3 (2.2–11.5)
Prostate 1.5 (1.3–1.8) 0.6 (0.5–0.8)
Leukaemia 1.3 (0.8–2.0) 1.8 (0.6–3.5)
Lymphoma 1.2 (0.9–1.5) 1.6 (1.2–2.4)
Lung 1.0 (0.8–1.2) 0.8 (0.6–1.1)
Sarcoma 1.0 (0.5–2.1) 1.9 (0.4–4.5)
Stomach 1.0 (0.7–1.5) 0.8 (0.3–1.9)
Liver 0.9 (0.4–2.0) 1.3 (0.5–3.3)
Bladder 0.8 (0.6–1.2) 0.7 (0.3–1.5)
Gallbladder 0.8 (0.3–2.1) 0.2 (0.0–0.7)
Myeloma 0.8 (0.4–1.3) 0.7 (0.3–1.0)
Pancreatic 0.8 (0.6–1.1) 1.4 (0.8–2.0)
Renal 0.7 (0.5–1.1) 0.2 (0.1–0.5)
Unknown
primary
0.7 (0.4–1.3) 0.5 (0.2–1.3)
Values41.0 are denoted in bold (indicating predominance of the patient over the primary
care interval). Bootstrap 95% confidence intervals for all estimates are presented. *Not
estimable because of median primary care interval values of 0.
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(voice hoarseness). These observations advocate the need for either
the continuation (where those exist) or the development of new
public health interventions aimed at shortening the patient interval
associated with those cancers. It should be noted that certain
cancers (e.g., laryngeal, oropharyngeal, melanoma and vulval)
associated with longest patient intervals also have high patient/
primary care interval length ratios.
It should nonetheless be emphasised that, beyond consideration
of evidence about the length of patient interval, the selection of
symptom – cancer pairs for public health awareness campaigns
ought to be informed by a number of factors, including the
consideration of the positive predictive value of their common
presenting symptoms. Existing campaigns cover symptoms with
positive predictive values in the order of 5% (NHS, 2014) – for
example, haemoptysis (7.5% and 4.3% for lung cancer in men and
women, respectively), haematuria (7.4% and 3.4% for bladder
cancer in men and women, respectively), and rectal bleeding (2.4%
for colorectal cancer in men) Jones et al, 2007. These comparisons
provide a pragmatic test about whether other symptom – cancer
pairs can be considered as candidates for public health campaigns.
Against this background, it should be noted that the positive
predictive value of dysphagia for oesophageal cancer in men is
5.7% (Jones et al, 2007), whereas that of post-menopausal bleeding
for endometrial cancer is 4.0% (Walker et al, 2013), that is values
that are comparable to those of other symptoms that are already
targeted by public health education campaigns. Good-quality
evidence about the positive predictive value of oral or vulval
ulceration or voice hoarseness in populations of patients consulting
in primary care is, however, currently lacking. We strongly support
that the selection, design, piloting and implementation of public
health awareness campaigns about symptoms likely to be due to cancer
require expert multi-disciplinary input (including from epidemiology,
psychology and primary care, alongside clinical specialities and
other relevant disciplines) and a robust evaluation framework.
On the other hand, several cancers have relatively long primary
care intervals, which also form a major part of overall pre-referral
intervals (i.e., lung, sarcoma, stomach, gallbladder, myeloma,
pancreatic, renal and cancer of unknown primary – these cancers
have a patient/primary care interval ratio of 1 or lower). In general,
this group is dominated by cancers that have been previously
described as ‘harder to suspect’ because most patients present with
symptoms with particularly low predictive values (Lyratzopoulos
et al, 2012). For these cancers, continuing efforts to support the
diagnostic process after presentation to a general practitioner are
needed, including the use of decision-support/risk assessment
tools, clinical audit/root cause analysis reviews and widening of
access to specialist diagnostics (Lyratzopoulos et al, 2014).
Although evidence about the length of the patient and the
primary care intervals, and their ratios, can inform the choice and
nature of interventions, there may also be opportunities for further
targeting such strategies by considering socio-demographic varia-
tion in either interval. For example, an ongoing breast symptom
awareness campaign is specifically addressing older women (NHS,
2014), as indirect evidence indicates that older women are likely to
have longer patient intervals for breast symptoms (Lyratzopoulos
and Abel, 2013). Another consideration to be borne in mind is that
the median does not capture all facets of variation in intervals
between cancers. For example, compared with other cancers,
testicular cancer has a typically short median patient interval (of
o2 weeks), whereas the upper quartile is longer compared with
most other cancers (42 months). This indicates that most people
with testicular cancer consult their GP quickly, but for a substantial
minority the interval between symptom recognition and consulting
a GP is long.
In conclusion, appreciating variation in the patient and primary
care intervals and their relative length can inform priorities for future
early diagnosis research and policy strategies, helping to optimally
use either a community-based or a health-care system-based focus, or
their combination, as applicable for different cancers. Commitment
to regular collection of data about both pre-referral diagnostic
intervals in representative samples of cancer patients is critical for the
evaluation and monitoring of such interventions.
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Figure 1. Visual summary of length of the patient, the primary care
and the pre-referral intervals by cancer. Bar length represents the size
of the interquartile interval, with median values depicted by a vertical
line. Cancers are ordered in ascending order of median patient interval.
Note that median patient intervals tend to be longer than primary care
intervals for most cancers, and very short primary care intervals are seen
for cancers such as breast, vulval and melanoma.
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Figure 2. Visual summary of ratios of means (patient/primary care
interval) and related 95% confidence intervals. Note that the y axis is
on the logarithmic scale.
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